Why J&J’s Kenvue Spinoff Is Just What the IPO Doctor Ordered
- Order Reprints
- Print Article
After months of waiting, investors finally have an initial public offering worth buying. It’s no highflying start-up, however. It’s Kenvue, the consumer health spinoff from Johnson & Johnson and it looks like a winner.
Already a subscriber? Sign In